Correspondence With Adam Feurstein Dear Shareholders

New Post Public Reply Private Reply Replies (2) Message Board
sox0407
354
Correspondence With Adam Feurstein

Dear Shareholders –

In light of an article written today by Adam Feuerstein of The Street, we thought it best that we share with our shareholders a copy of our correspondence with Mr. Feuerstein. See below. We feel that we answered his questions forthrightly and that his piece was written based on a selective interpretation of the data.

Cellceutix believes strongly that Prurisol, the focus of Mr. Feuerstein’s article, showed a promising signal in the Phase 2 proof-of-concept trial to merit advancement to a powered Phase 2b trial. This ongoing trial is a randomized, double-blind, parallel-group, placebo-controlled study with approximately 189 patients anticipated to be enrolled and designed to show statistical significance. We anticipate reporting interim analysis in the 1st half of 2017.

A link to the Phase 2b trial assessing the efficacy and safety of Oral Prurisol in moderate-to-severe chronic plaque psoriasis can be found below:

https://clinicaltrials.gov/ct2/show/NCT02949388

We appreciate the continued support of Cellceutix shareholders and look forward to sharing more results as our first-in-class drug candidates continue to advance in later-stage clinical trials.

Sincerely,
Leo Ehrlich
Cellceutix, CEO

CORRESPONDENCE WITH ADAM FEUERSTEIN

From: Adam Feuerstein --
Leo --

Can you please clarify some of the data you've announced from the ph2 psoriasis study?

What percentage of patients in each of the 3 Prurisol dose arms achieved the ITT primary endpoint ( >=2 point improvement in IGA rating at 84 days). What was the corresponding response rate for the placebo arm?

Did any of the Prurisol doses demonstrate a statistically significant improvement over placebo on the primary endpoint, as measured by the ITT analysis?

Adam

CELLCEUTIX:

Hi Adam,

Thank you for the clinical questions that you sent to us at Cellceutix. Leo won’t be back until late this evening and asked me to reply. I’m glad to make your acquaintance. I was recruited by Cellceutix and joined in June 2016 as President and Chief Medical Officer. Previously at Novartis in Basel, Switzerland, the Cosentyx program was in my group, so I have significant experience with psoriasis clinical trials and know the challenges needed to cross the FDA finish line. With me, I brought along to Cellceutix another senior ex-Novartis team member. What compelled me to take the Cellceutix position was the very chart you sent Leo. It shows patients transitioning early on.

I believe most of your questions are answered in a slide-deck presented at a conference in September 2016 that can be accessed through our website or through the following link:

https://static1.squarespace.com/static/571535...2016-u.pdf

As far as the specific reasons for attrition, there were various reasons and we should have that information more readily available when our CSR is completed. The attrition rate at one site was significantly higher than the other sites.

Please note our ongoing Phase 2b is a powered study treating moderate-to-severe psoriasis. Total daily oral dosing is increase from Prurisol 200 mg to 300 mg per day, 400 mg per day, and placebo (3:1:3 randomization, respectively). The trial is a randomized, double-blind, parallel-group, placebo-controlled study with approximately 189 patients anticipated to be enrolled. Treatment duration is 12 weeks (84 days), with a post-treatment follow-up 4 weeks after the end of treatment.
Primary efficacy will be evaluated using PASI. Interim analysis of 6-week data with readout is anticipated in 2Q2017, with full study top-line results in 3Q2017.
We have selected a very capable CRO which I have used previously. The patient population of moderate-to-severe psoriasis is likely to have a more robust PASI 75 response than mild-to-moderate psoriasis. That is to be expected as the IGA (-2) decline was seen in greater numbers in moderate psoriasis patients than mild psoriasis patients in the Phase 2a study.

I would be happy to further address whatever I can in a tc if that would be helpful.

Kind regards,
Art

From: Adam Feuerstein
Is there a reason why Cellceutix hasn't disclosed the details of the phase 2a study more broadly than just dropping this slide deck onto the web site?
There are huge and troubling disparities between the negative data in the slide deck versus the way Leo and the company have described the Prurisol data publicly in press releases and SEC filings.
The study failed its primary endpoint.
The endpoint upon which you claim study success -- IGA response in the 200 mg dose at 84 weeks -- isn't pre-specified.
The 12.6 percentage point difference between Prurisol and placebo was not statistically significant. Four more responders numerically than placebo, with patients missing.... really?
At 12 weeks, placebo performed better than your 50 mg and 100 mg Prurisol dose arms. No dose response?
The AEs are alarming! Liver enzyme elevations all over the place. And now you're going to a higher dose?
How does these data gibe with anything Leo has said about the potential for this drug to be a competitor to Otezla?
Good luck with the next study.
Adam

CELLCEUTIX:

Hi Adam,

Thanks for looking at our data previously presented at a clinical meeting in Boston that we shared with you through our website and link. The Phase 2a study was a proof-of-concept. It was not a powered study and as such your comments regarding statistical significance don’t really apply. In such a study, the goal is to see the efficacy signal that we observed at 200mg and examine it more carefully as we are currently doing in our ongoing Phase 2b study. Our primary endpoint was specified in our criteria for evaluation in our protocol and was met in the 200mg group, suggesting that it will compare favorably against existing treatments. Please note that changes in liver function that you mentioned were also seen in the placebo group and make meaningful conclusions difficult.

I hope that you will look forward to the efficacy and safety data that we are generating in the ongoing Phase 2b study to answer the kinds of questions that you pose. Please stay tuned.

Thanks.

Kind regards,
Art

From: Adam Feuerstein

You didn't answer my questions.

Is there a reason why Cellceutix hasn't disclosed the details of the phase 2a study more broadly than just dropping this slide deck onto the web site?
How does these data gibe with anything Leo has said about the potential for this drug to be a competitor to Otezla?
Is there a reason why Cellceutix hasn't disclosed the details of the phase 2a study more broadly than just dropping this slide deck onto the web site?

CELLCEUTIX:

Please see:

Press releases:
http://www.cellceutix.com/press-release/2016/...onferences

http://www.cellceutix.com/press-release/2016/...y-endpoint

How does these data gibe with anything Leo has said about the potential for this drug to be a competitor to Otezla?

Otezla efficacy is only modest.

Kind regards,

Art

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Dont-give-up.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading